ProCE Banner Activity

CE / CME

Updates on FDA-Approved Obesity Pharmacotherapies

Video

Experts review new and FDA-approved pharmacotherapy for the treatment of obesity and describe best practices for use.

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 09, 2023

Expiration: June 08, 2024

No longer available for credit.

Share

Faculty

Megan Adelman

Megan Adelman, PharmD, BCPS, BCGP, CDCES

Clinical Pharmacist - Family Medicine
Center for Family Medicine
Cleveland Clinic Akron General
Akron, Ohio

W. Scott Butsch

W. Scott Butsch, MD, MSc

Director of Obesity Medicine 
Bariatric and Metabolic Institute
Cleveland Clinic 
Cleveland, Ohio 

Susan M. Tiso

Susan M. Tiso, DNP, APRN, FNP-BC, FAANP

Clinical Professor, Retired
Sue & Bill Gross School of Nursing
Family Nurse Practicioner, Retired
Family Medicine 
University of California, Irvine 
Irvine, California 

Provided by

This activity is provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, ProCE, LLC and Q Synthesis.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

Practicing Clinicians Exchange

ProCE Banner

ProCE, LLC

ProCE Banner

Q Synthesis LLC

ProCE Banner

Target Audience

This activity is intended for a broad audience of interprofessional healthcare professionals who provide care, education, and counseling for patients with obesity including primary care physicians, nurse practitioners, physician associates/physician assistants, and pharmacists.

Program Learning Goal

The goal of this initiative is to increase the percentage of adults with obesity who receive guideline recommended obesity care by 15% among participating clinic sites by the conclusion of the project. This will be determined by a series of 4 quality measures. In addition, individual clinic teams participating in the project as QI teams will establish tailored process improvement goals in order to address their local gaps to improve care and patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop measurable and comprehensive treatment plans for patients with obesity

  • Apply the latest efficacy and safety data to select antiobesity medications for appropriate patients with obesity

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Megan Adelman, PharmD, BCPS, BCGP, CDCES

Clinical Pharmacist - Family Medicine
Center for Family Medicine
Cleveland Clinic Akron General
Akron, Ohio

Megan Adelman, PharmD, BCPS, BCGP, CDCES, has no relevant financial relationships to disclose.

Contributing Author

W. Scott Butsch, MD, MSc

Director of Obesity Medicine 
Bariatric and Metabolic Institute
Cleveland Clinic 
Cleveland, Ohio 

W. Scott Butsch, MD, MSc: consultant/advisor/speaker: Novo Nordisk.

Susan M. Tiso, DNP, APRN, FNP-BC, FAANP

Clinical Professor, Retired
Sue & Bill Gross School of Nursing
Family Nurse Practicioner, Retired
Family Medicine 
University of California, Irvine 
Irvine, California 

Susan Tiso, DNP, APRN, FNP-BC, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC, ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis have no relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 09, 2023, through June 08, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. View and study the content in its entirety.

4. Submit answers to the posttest questions and evaluation questions online.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


Physician Continuing Medical Education 
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-9999-23-151-H01-P  
Type of Activity: Application 

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 08, 2024. PAs should only claim credit commensurate with the extent of their participation.